HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) A correction has been published Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gayed, I. Articles by Podoloff, D. Search for Related Content PubMed PubMed Citation Articles by Gayed, I. Articles by Podoloff, D.

The Role of ¹⁸F-FDG PET in Staging and Early Prediction of Response to Therapy of Recurrent Gastrointestinal Stromal Tumors

¹ Department of Nuclear Medicine, M.D. Anderson Cancer Center, University of Texas, Houston, Texas
² Department of Diagnostic Radiology, M.D. Anderson Cancer Center, University of Texas, Houston, Texas
³ Department of Biostatistics, M.D. Anderson Cancer Center, University of Texas, Houston, Texas

View larger version (123K): [in a new window]   FIGURE 1. 18F-FDG PET and CT scans of patient with metastatic GIST in abdomen and liver before therapy (A and B); at 12 mo of imatinib mesylate therapy (C and D); and at 13 mo after withdrawal of imatinib mesylate for 1 mo (E and F). Maximum SUV of abdominal mass changed from 10.1 (A) to 1.3 (C) to 4.5 (E), and tumor size in longest dimension changed from 10.9 cm (B) to 11.3 cm (D) to 11.5 cm (F).